

Publikationen 2002

Anghelescu I, Klawe C, Dahmen N (2002) Venlafaxine in a patient with idiopathic leukopenia and mirtazapine-induced severe neutropenia. *J Clin Psychiatry* 63: 838

Anghelescu I, Klawe C, Szegedi A (2002) Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior. *J Clin Psychopharmacol*: 521-524

Benkert O, **Müller MJ, Szegedi A** (2002) An overview of the clinical efficacy of mirtazapine. *Hum Psychopharmacol Clin Exp* 17: S23-S26

Benkert O, **Szegedi A, Müller MJ** (2002) Antidepressant drugs. In: Smelser JN, Baltus JB (eds). *International Encyclopedia of the Social and Behavioral Sciences*. Pergamon Press, London, 1: 529-535

Dahmen N, Epplen JT (2002) Narkolepsie. In: Rieß O, Schöls L (Hrsg) *Neurogenetik*. Stuttgart, Kohlhammer. S. 278-284

Dahmen N, Jungblut P, Fischer V, Schrank M, Reuss S, Rujescu D, **Hiemke C** (2002) Detection of TOAD-64 in adult rat brain as revealed by two-dimensional protein gel electrophoresis followed by MALDI mass spectrometry: possible modulatory effect of chronic haloperidol treatment *Prog Neuropsychopharmacol Biol Psychiatry* 26: 693-698

Dahmen N, Kasten M, Mittag K, Müller MJ (2002) Narcoleptic and schizophrenic hallucinations: Implications for differential diagnosis and pathophysiology. *Eur J Health Econom* 3: S94-S98

Dahmen N, Kasten M, Müller MJ, Mittag K (2002) Frequency and dependence on body posture of hallucinations and sleep paralysis in a community sample. *J Sleep Res* 11: 179-180

Dahmen N, Michaelis L (2002) Haben Mobiltelefone einen Einfluß auf die Narkolepsie? *Der Wecker (Deutsche Narkolepsie-Gesellschaft)* 32: 15-20

Davids E, **Hevers W**, Damgen K, Zhang K, Tarazi FI, **Lüddens H** (2002) Organotypic rat cerebellar slice culture as a model to analyze the molecular pharmacology of GABA_A receptors. *Eur Neuropsychopharmacol* 12: 201-208

Davids E, Müller MJ, Rollmann N, Burkart M, Regier-Klein E, Szegedi A, Benkert O, Maier W (2002) Syndrome profiles in alcoholism and panic disorder with or without agoraphobia: An explorative family study. *Prog Neuropsychopharmacol Biol Psychiatry* 26: 1079-1087

Dielentheis TF, Priebe S (2002) Patientenmerkmale, Behandlungsdauer und Kosten in einem gemeindepsychiatrischen Versorgungsmodell – eine Analyse über 23 Jahre. *Psychiatrische Praxis* 29: 186-193

Eggers V, Tio J, Neumann T, Pragst F, Müller C, **Schmidt LG**, Kox WJ, Spies CD (2002) Blood alcohol concentration for monitoring ethanol treatment to prevent alcohol withdrawal in the intensive care unit. *Intensive Care Med* 28: 1475-1482

Fehr C, Shirley RL, Belknap JK, Crabbe JC, Buck KJ (2002) Congenic mapping of alcohol and pentobarbital withdrawal liability loci to a <1 centimorgan interval of murine chromosome 4: identification of Mpdz as a candidate gene. *J Neurosci* 22: 3730-3738

Fellgiebel A, Schmidt LG (2002) Nutzen von Galantamin (Reminyl) in der Therapie von vaskulärer und gemischter Demenz. *Arzneiverordnung in der Praxis* 3: 9

Gastpar M, Bonnet U, Böning J, Mann K, **Schmidt LG**, Soyka M, Wetterling T, Kielstein V, Labriola D, Croop R (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. *J Clin Psychopharmacol* 22: 592-598

Germeyer S, Birke A, **Schmitt U, Dahmen N, Hiemke C**, Havemann-Reinecke U (2002) New dopamine D2 receptor polymorphisms in rats and association with apomorphine-induced stereotypies. *Brain Res* 926: 1-9

Grözinger M, Beersma DG, **Fell J, Röschke J** (2002) Is the nonREM-REM sleep cycle reset by forced awakenings from REM sleep? *Physiol Behav* 77: 341-347

Grözinger M, Kögel P, Röschke J (2002) Effects of REM sleep awakenings and related waking paradigms on the ultradian sleep cycle and the symptoms in depression. *J Psychiatr Res* 36: 299-308

Gründer G, Benkert O (2002) Prolactin secretion is not a core dimension of "atypicality". *Psychopharmacology (Berl)* 162: 93

Härtter S, Hiemke C (2002) Pharmakokinetik, Interaktionspotential und TDM. *Pharmazie in unserer Zeit* 31: 546-557

Hevers W, Lüddens H (2002) Pharmacological heterogeneity of gamma-aminobutyric acid receptors during development suggests distinct classes of rat cerebellar granule cells in situ. *Neuropharmacology* 42: 34-47

Hiemke C (2002) Citalopram/Excitalopram, Paroxetin, Fluoxetin, Fluvoxamin, Sertralin, Nefazodon. In: Riederer P, Laux G, Pöldinger W (Hrsg). *Neuro-Psychopharmaka*, Bd. 3. Springer, Wien. S. 305-338

Hiemke C (2002) Cytochrom P450 – Interaktionen mit Antidepressiva. In: Möller H-J, Müller WE, Rütger E (Hrsg) *Moderne Antidepressiva*. Thieme, Stuttgart. S. 17-34

Hiemke C (2002) Reboxetin, Viloxazin. In: Riederer P, Laux G, Pöldinger W (Hrsg). *Neuro-Psychopharmaka*, Bd. 3. Springer, Wien. S. 394-400

Hiemke C (2002) Therapeutisches Drug Monitoring unter dem Aspekt des Qualitätsmanagements. In: Gastpar M, Müller WE (Hrsg) *Depressionen*. Springer, Berlin. S. 97-103

Hiemke C, Laux G (2002) Therapeutisches Drug-Monitoring von Antidepressiva. In: Riederer P, Laux G, Pöldinger W (Hrsg). Neuro-Psychopharmaka, Bd. 3. Springer, Wien. S. 911-922

Hiemke C, Peled A, Jabarin M, Hadjez J, **Weigmann H**, **Härtter S**, Modai I, Ritsner M, Silver H (2002) Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. *J Clin Psychopharmacol* 22: 502-506

Himmerich H, **Müller MJ**, Anghelescu I, **Klawe C**, **Scheurich A**, **Szegedi A** (2002) Dimensionen des Michigan Alcoholism Screening Tests (MAST): Faktorenanalytische Ergebnisse einer deutschen Version. *Suchtmed* 4: 205-212

Himmerich H, **Müller MJ**, Anghelescu I, **Klawe C**, **Szegedi A** (2002) Erythrozytenzahl und Vitamin B2-Serumspiegel korrelieren bei männlichen alkoholkranken Patienten. *Suchtmed* 4: 152-156

Kampen M van, Kramer M, **Hiemke C**, Flügge G, Fuchs E (2002) The chronic psychosocial stress paradigm in male tree shrews: evaluation of a novel animal model for depressive disorders. *Stress* 5: 37-46

Korpi ER, **Gründer G**, **Lüddens H** (2002) Drug interactions at GABA(A) receptors. *Prog Neurobiol* 67: 113-159

Korpi ER, Mihalek RM, Sinkkonen ST, Hauer B, **Hevers W**, Homanics GE, Sieghart W, **Lüddens H** (2002) Altered receptor subtypes in the forebrain of GABA(A) receptor delta subunit-deficient mice: recruitment of gamma 2 subunits. *Neuroscience* 109: 733-743

Lange-Asschenfeldt C, **Weigmann H**, **Hiemke C**, **Mann K** (2002) Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. *J Clin Psychopharmacol* 22: 440-441

Mann K, **Röschke J**, **Wagner P** (2002) Einfluß hochfrequenter elektromagnetischer Felder auf das Schlaf-EEG des Menschen. In: Bundesanstalt für Arbeitsschutz und Arbeitsmedizin (Hrsg). Bremerhaven, Wirtschaftsverlag NW. S. 163-170

Mann K, Thüroff JW (2002) Die erektile Dysfunktion. *Ärzteblatt Rheinland-Pfalz* 7: 23-26

Martin MJ, Heymann C, Neumann T, **Schmidt L**, Soost F, Mazurek B, Böhm B, Marks C, Helling K, Lenzenhuber E, Müller C, Kox WJ, Spies CD (2002) Preoperative evaluation of chronic alcoholics assessed for surgery of the upper digestive tract. *Alcohol Clin Exp Res* 26: 836-840

Müller MJ (2002) Finite biprediction tests in treatment-response contingency tables. *Adv & Appl in Stat* 2: 1-18

Müller MJ (2002) Overlap between emotional blunting, depression, and extrapyramidal symptoms in schizophrenia. *Schizophr Res* 57: 307-309

Müller MJ (2002) PANSS positive and negative syndrome scale. In: Brähler E, Schumacher J, Strauß B (Hrsg) Diagnostische Verfahren in der Psychotherapie. Hogrefe, Göttingen. S. 267-271

Müller MJ, Kienzle B, Dahmen N (2002) Depression, emotional blunting, and akinesia in schizophrenia: Overlap and differentiation. Eur J Health Econom 3: S99-S103

Müller MJ, Schanz B (2002) Patientenzufriedenheit in der Psychiatrie. Psych Pflege 8: 319-322

Müller MJ, Schlösser, R, Kapp-Steen G, Schanz B, Benkert O (2002) Patients' satisfaction with psychiatric treatment: comparison between an open and a closed ward. Psychiatric quarterly 73: 93-107

Müller MJ, Szegedi A (2002) Effects of interrater reliability of psychopathologic assessment on power and sample size calculations in clinical trials. J Clin Psychopharmacol 22: 318-325

Müller MJ, Wetzel H, Benkert O (2002) Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis. Int Clin Psychopharmacol 17: 249-261

Müller MJ, Wetzel H, Eich FX, Rein W, Puech A, Benkert O; Amisulpride Study Group (2002) Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 22: 554-560

Plewnia C, Hoppe J, **Hiemke C**, Bartels M, Cohen LG, Gerloff C (2002) Enhancement of human cortico-motoneuronal excitability by the selective norepinephrine reuptake inhibitor reboxetine. Neurosci Lett 330: 231-234

Priebe S, **Dielentheis TF** (2002) Institutionalierungsindex – eine einfache Methode zur Schätzung von direkten Behandlungskosten in Institutionen der Gemeindepsychiatrie. Psychiatrische Praxis 29: 420-423

Röschke J, Mann K (2002) The sleep EEG's microstructure in depression: alterations of the phase relations between EEG rhythms during REM and NREM sleep. Sleep Medicine 3: 501-505

Samochowicz J, Kucharska-Mazur J, Kaminski R, Smolka M, Rommelspacher H, Wernicke C, Tymicz A, **Schmidt LG** (2002) Norepinephrine transporter gene polymorphism is not associated with susceptibility to alcohol dependence. Psychiatry Res 111: 229-233

Samochowicz J, Kucharska-Mazur J, Rybakowski F, Ostapowicz A, Horodnicki J, Rozpara M, Kaminski R, Skrzypinska A, Arentowicz G, Rommelspacher H, **Schmidt LG** (2002) Norepinephrine transporter polymorphism and personality trait of reward dependence in male alcoholics. Pharmacopsychiatry 35: 195-196

Scheurich A, Meyer TD, **Müller MJ**, Trautmann B, Wetzel H, Dreher M, Hautzinger M, **Szegedi A** (2002) Strukturierte Interviews zur Erhebung der aktuellen Trinkmenge und des aktuellen Trinkverhaltens (Form 90). In: Glöckner-rist A, Rist F, Kufner H (Hrsg) Elektronischen Handbuchs zu Erhebungsinstrumenten im Suchtbereich (EHES, Version 2.00). Mannheim: Zentrum für Umfragen, Methoden und Analysen. Internet: www.gesis.org/Methodenberatung/ZIS/index.html

Schlösser R, **Gründer G**, Anghelescu I, Hillert A, Ewald-Gründer S, **Hiemke C**, Benkert O (2002) Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. *Neuropsychobiology* 46: 33-40

Schmidt LG (2002) Advances in the treatment of alcohol dependence. *Current Opinion in Psychiatry* 15: 255-260

Schmidt LG (2002) Früherkennung der Demenzsyndrome. *Der Kassenarzt* 42 Heft 34/35: 25-28

Schmidt LG, Gastpar M (2002) Die Behandlung substanzbezogener Störungen im Rahmen des AWWF-Leitlinien-Prozesses. *Suchttherapie*: S107-S111

Schmidt LG, Grohmann R (2002) AMSP – Ein Modell zur Verbesserung der Arzneimittelsicherheit für die Epileptologie? *Aktuelle Neurologie* 29: S54-S57

Schmidt LG, Kuhn S, Smolka M, Schmidt K, Rommelspacher H (2002) Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence. *Prog Neuropsychopharmacol Biol Psychiatry* 26: 209-217

Schmidt LG, Mundle G, Banger M, Stetter F, Soyka M, Veltrup C, Mann K (2002) Die „Qualifizierte Entgiftung Alkoholkranker“ – Im Lichte der Entwicklung von Behandlungsleitlinien für substanzbezogene Störungen. *Z ärztl Fortbild Qualitätssich* 96: 295-300

Schmidt LG, Samochowiec J, Finckh U, Fiszer-Piosik E, Horodnicki J, Wendel B, Rommelspacher H, Hoehe MR (2002) Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcoholdependence. *Drug Alcohol Depend* 65: 221-224

Schmitt U, **Hiemke C** (2002) Tiagabine, a gamma-amino-butyric acid transporter inhibitor impairs spatial learning of rats in the Morris water-maze. *Behav Brain Res* 133: 391-394

Schmitt U, **Lüddens H**, **Hiemke C** (2002) Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. *J Neural Transm* 109: 871-880

Schmitt U, Waldhofer S, Weigelt T, **Hiemke C** (2002) Free-choice ethanol consumption under the influence of GABAergic drugs in rats. *Alcohol Clin Exp Res* 26: 457-462

Silver H, Shlomo N, **Hiemke C**, Rao ML, Ritsner M, Modai I (2002) Schizophrenic patients who smoke have a faster finger tapping rate than non-smokers. *Eur Neuropsychopharmacol* 12: 141-144

Szegedi A (2002) Psychopharmaka und Sexualität. In: Hartwich P, Haas S (Hrsg) Sexuelle Störungen und Probleme bei psychisch Kranken. Verlag Wissenschaft und Praxis, Sternenfels. S. 97-111

Wernicke C, Smolka M, Gallinat J, Winterer G, **Schmidt LG**, Rommelspacher H (2002) Evidence for the importance of the human dopamine transporter gene for withdrawal symptomatology of alcoholics in a German population. *Neurosci Lett* 333: 45-48

Yokoi F, **Gründer G**, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF (2002) Dopamine D₂ and D₃ receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [¹¹C]raclopride. *Neuropsychopharmacology* 27: 248-259